Thomas Story & Son’s Amgen AMGN Stock Holding History

Thomas Story & Son’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$471K	Hold	1,300	–	–	0.17%	40
2026 Q1	$457K	Hold	1,300	–	–	0.18%	40
2025 Q4	$426K	Hold	1,300	–	–	0.16%	42
2025 Q3	$367K	Hold	1,300	–	–	0.13%	43
2025 Q2	$363K	Sell	1,300 -25	-2%	-$7.08K	0.14%	44
2025 Q1	$413K	Hold	1,325	–	–	0.16%	44
2024 Q4	$345K	Hold	1,325	–	–	0.14%	45
2024 Q3	$427K	Hold	1,325	–	–	0.17%	44
2024 Q2	$414K	Hold	1,325	–	–	0.18%	45
2024 Q1	$377K	Hold	1,325	–	–	0.16%	45
2023 Q4	$382K	Hold	1,325	–	–	0.18%	45
2023 Q3	$356K	Hold	1,325	–	–	0.17%	46
2023 Q2	$294K	Hold	1,325	–	–	0.13%	52
2023 Q1	$320K	Hold	1,325	–	–	0.16%	49
2022 Q4	$348K	Hold	1,325	–	–	0.18%	47
2022 Q3	$299K	Hold	1,325	–	–	0.16%	49
2022 Q2	$322K	Sell	1,325 -75	-5%	-$18.4K	0.15%	50
2022 Q1	$339K	Hold	1,400	–	–	0.13%	53
2021 Q4	$315K	Hold	1,400	–	–	0.12%	57
2021 Q3	$298K	Sell	1,400 -100	-7%	-$23K	0.12%	58
2021 Q2	$366K	Hold	1,500	–	–	0.14%	52
2021 Q1	$373K	Hold	1,500	–	–	0.14%	50
2020 Q4	$345K	Hold	1,500	–	–	0.14%	49
2020 Q3	$381K	Hold	1,500	–	–	0.17%	46
2020 Q2	$354K	Hold	1,500	–	–	0.17%	47
2020 Q1	$304K	Hold	1,500	–	–	0.18%	47
2019 Q4	$362K	Hold	1,500	–	–	0.18%	42
2019 Q3	$290K	Hold	1,500	–	–	0.15%	47
2019 Q2	$276K	Hold	1,500	–	–	0.14%	47
2019 Q1	$285K	Hold	1,500	–	–	0.15%	44
2018 Q4	$292K	Hold	1,500	–	–	0.18%	45
2018 Q3	$311K	Hold	1,500	–	–	0.16%	45
2018 Q2	$277K	Hold	1,500	–	–	0.16%	47
2018 Q1	$256K	Hold	1,500	–	–	0.15%	48
2017 Q4	$261K	Sell	1,500 -8,057	-84%	-$1.43M	0.15%	48
2017 Q3	$1.78M	Hold	9,557	–	–	0.96%	30
2017 Q2	$1.65M	Hold	9,557	–	–	0.97%	27
2017 Q1	$1.57M	Hold	9,557	–	–	0.89%	28
2016 Q4	$1.4M	Buy	9,557 +200	+2%	+$30.1K	0.84%	27
2016 Q3	$1.56M	Hold	9,357	–	–	0.96%	25
2016 Q2	$1.42M	Hold	9,357	–	–	0.88%	25
2016 Q1	$1.4M	Hold	9,357	–	–	0.86%	28
2015 Q4	$1.52M	Hold	9,357	–	–	0.95%	27
2015 Q3	$1.29M	Hold	9,357	–	–	0.85%	30
2015 Q2	$1.44M	Hold	9,357	–	–	0.9%	30
2015 Q1	$1.5M	Hold	9,357	–	–	0.94%	29
2014 Q4	$1.49M	Hold	9,357	–	–	0.89%	30
2014 Q3	$1.31M	Hold	9,357	–	–	0.82%	34
2014 Q2	$1.11M	Hold	9,357	–	–	0.68%	34
2014 Q1	$1.15M	Sell	9,357 -200	-2%	-$24.3K	0.63%	39
2013 Q4	$1.09M	Sell	9,557 -443	-4%	-$50.4K	0.6%	39
2013 Q3	$1.12M	Hold	10,000	–	–	0.69%	35
2013 Q2	$987K	Buy	+10,000	New	+$1.04M	0.62%	37

Other funds holding AMGN

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

FFM

Forum Financial Management Lombard, Illinois $7.79B AUM 20.38% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Sarasin & Partners London, United Kingdom $8.54B AUM 9.6% 1-Year Est. Return

Thomas Story & Son's AMGN Position: Q2 2026 in Review

Thomas Story & Son held its Amgen (AMGN) position steady in Q2 2026 at 1,300 shares worth $471K. The position accounts for 0.17% of the portfolio, ranked #40.

Thomas Story & Son first reported a position in AMGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.78M in Q3 2017. 1,355 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

Thomas Story & Son held 1,300 shares of Amgen worth $471K as of Q2 2026.
Thomas Story & Son left its Amgen share count unchanged in Q2 2026.
Amgen made up 0.17% of Thomas Story & Son's portfolio in Q2 2026, its #40 holding.
Thomas Story & Son first reported a position in Amgen in Q2 2013 and has held it in 53 quarters since.
Thomas Story & Son's Amgen position peaked at $1.78M in Q3 2017.
1,355 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Thomas Story & Son's 13F filing for Q2 2026, filed 23 Jul 2026.